Study on Pharmacodynamic Parameter and Tolerability With Subcutaneous Immunotherapy in Grass Pollen Allergic Patients
Launched by ALK-ABELLÓ A/S · Mar 5, 2009
Trial Information
Current as of June 13, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • A clinical history of grass pollen induced allergic rhinoconjunctivitis of two years or more requiring treatment during the grass pollen season
- • Lack of adequate relief with symptomatic medication during the previous grass pollen season
- • Positive Skin Prick Test (SPT) response to Phleum pratense (wheal diameter \>= 3mm) currently performed or not older than 60 days before screening
- Exclusion Criteria:
- • FEV1 \< 70% of predicted value at screening
- • Bronchial asthma corresponding to GINA step 3 or more, even if controlled
- • History of asthma exacerbation or emergency visit or admission for asthma in the previous 12 months
- • Previous treatment by immunotherapy with grass pollen allergen or any other allergen within the previous 5 years
- • Exclusion criteria in accordance with contraindications in the SPC of ALK-Flex SQ
About Alk Abelló A/S
ALK-Abelló A/S is a global biopharmaceutical company specializing in the development of innovative allergy immunotherapy treatments. With a strong commitment to improving patient outcomes, ALK focuses on research and development of products that address various allergic conditions, including asthma, rhinitis, and food allergies. Leveraging advanced scientific expertise and a robust pipeline of therapies, ALK aims to enhance the quality of life for individuals affected by allergies while adhering to the highest standards of safety and efficacy in clinical trial practices. The company is dedicated to advancing the field of allergy treatment through collaboration and innovation.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Erfurt, Thueringen, Germany
Patients applied
Trial Officials
Kirsten Jung, MD
Principal Investigator
Private practice, Erfurt, Germany
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials